cefuroxime + ceftriaxone

cefuroxime + ceftriaxone is a combination antibiotic regimen utilized as the standard of care in clinical research conducted by the Nazarbayev University Medical Center for pediatric patients with acute bronchitis. Cefuroxime is a second-generation cephalosporin, while ceftriaxone is a third-generation cephalosporin. Both drugs function by inhibiting bacterial cell wall synthesis through the competitive inhibition of penicillin-binding proteins (PBPs), which are essential for the cross-linking of peptidoglycan layers. This specific therapeutic combination is being studied in conjunction with dietary supplements to mitigate antibiotic-associated gut microbiome disruption.

Other names

Standard antibiotic therapy